FrancophonIA/ELRC3.0 huggingface dataset:
English: No. Advertising of medicines is controlled by medicines regulatory authorities in Member States and other national regulatory bodies, together with self-regulation by the pharmaceutical industry.
Slovenian: Ne. Oglaševanje zdravil ob samoregulaciji farmacevtske industrije nadzirajo regulativni organi za zdravila v državah članicah in drugi nacionalni regulativni organi.
English: Questions about medicines
Slovenian: Vprašanja o zdravilih
English: How are cosmetics evaluated?
Slovenian: Kako se vrednotijo kozmetični izdelki?
English: The Agency suggests that you discuss your treatment with a healthcare professional, such as a doctor or pharmacist.
Slovenian: Agencija priporoča, da se o možnostih zdravljenja pogovorite z zdravstvenim strokovnjakom, na primer zdravnikom ali farmacevtom.
English: However, the Agency can be consulted on medical devices that contain medicinal substances.
Slovenian: Agencijo pa lahko zaprosijo za mnenje, če medicinski pripomoček vsebuje zdravilne učinkovine.
English: To find information on nationally authorised medicines, contact the medicines regulatory agency in your country;
Slovenian: Za informacije o zdravilih, odobrenih z nacionalnim postopkom, se obrnite na regulativni organ za zdravila v svoji državi;
English: In the European Union (EU), herbal medicines are authorised by medicines regulatory authorities in Member States.
Slovenian: Zdravila rastlinskega izvora v Evropski uniji (EU) odobrijo regulativni organi za zdravila v posameznih državah članicah.
English: How are medical devices evaluated?
Slovenian: Kako se vrednotijo medicinski pripomočki?
English: For information on clinical trials, talk to your doctor or nurse.
Slovenian: Več informacij o kliničnih preskušanjih dobite pri zdravniku ali medicinski sestri.
English: Medical devices are evaluated by the medicines regulatory authorities in each Member State.
Slovenian: Medicinske pripomočke vrednotijo regulativni organi za zdravila v vsaki državi članici posebej.
English: For information on how to report a side effect in your country, please consult the appropriate authority.
Slovenian: Za informacije o načinu prijave neželenega učinka v svoji državi se obrnite na pristojni organ.
English: Following a positive recommendation from the Agency, the European Commission takes around two months to approve a medicine.
Slovenian: Evropska komisija odobri zdravilo približno dva meseca po izdaji pozitivnega mnenja agencije.
English: The Agency suggests that you discuss these issues with a healthcare professional, such as your doctor or pharmacist.
Slovenian: Priporoča pa, da se o tem pogovorite z zdravstvenim delavcem, na primer zdravnikom ali farmacevtom.
English: • patents on medicines;
Slovenian: • patentov zdravil;
English: • medical devices;
Slovenian: • medicinskih pripomočkov;
English: You can also find information on side effects seen with a medicine in the package leaflet.
Slovenian: Informacije o neželenih učinkih pri uporabi zdravila lahko najdete tudi v navodilu za uporabo.
English: You may not be able to obtain a complete list of available treatment options for a specific condition by searching on the Agency's website.
Slovenian: Z iskanjem po spletnih straneh agencije morda ne boste pridobili celotnega seznama vseh razpoložljivih možnosti zdravljenja za posamezno bolezen.
English: Page 8/15
Slovenian: stran 8/15
English: How are herbal medicines evaluated?
Slovenian: Kako se vrednotijo zdravila rastlinskega izvora?
English: You may wish to consult the EU Clinical Trials Register for information on authorised clinical trials that are ongoing.
Slovenian: Podatke o odobrenih kliničnih preskušanjih, ki trenutno potekajo, najdete v registru kliničnih preskušanj EU.
English: Contact the medicines regulatory authorities in these countries to get more information on the availability of medicines in their territories.
Slovenian: Več informacij o razpoložljivosti zdravil na teh območjih je na voljo pri regulativnih organih za zdravila v zadevnih državah.
English: Page 7/15
Slovenian: stran 7/15
English: Page 11/15
Slovenian: stran 11/15
English: Page 9/15
Slovenian: stran 9/15
English: Questions about medical advice
Slovenian: Vprašanja o zdravniški pomoči
English: Page 6/15
Slovenian: stran 6/15
English: Page 4/15
Slovenian: stran 4/15
English: Page 12/15
Slovenian: stran 12/15
English: Page 13/15
Slovenian: stran 13/15
English: Page 14/15
Slovenian: stran 14/15
English: Page 5/15
Slovenian: stran 5/15
English: When is the Agency open?
Slovenian: Kakšen je delovni čas agencije?
English: Page 10/15
Slovenian: stran 10/15
English: • the pricing of medicines;
Slovenian: • cen zdravil;
English: Medicines regulatory authorities in Member States may be able to provide you with this information.
Slovenian: Te informacije lahko dobite pri regulativnih organih za zdravila v posameznih državah članicah.
English: Page 15/15
Slovenian: stran 15/15
English: The medicines regulatory authorities in Member States may be able to provide information on sales of a medicine.
Slovenian: Podatke o prodaji zdravila lahko dobite pri regulativnih organih za zdravila v posameznih državah članicah.
English: I am experiencing a side effect from a medicine.
Slovenian: Pri jemanju zdravila so se pojavili neželeni učinki.
English: • herbal supplements;
Slovenian: • nadomestkov rastlinskega izvora;
English: The full EPAR for Ivabradine Zentiva can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Ivabradine Zentiva je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Also, the doctor should consider stopping treatment if the medicine has only a limited effect on reducing symptoms or reducing the heart rate.
Slovenian: Zdravnik bi moral prav tako razmisliti o prekinitvi zdravljenja, če zdravilo le omejeno blaži simptome ali znižuje srčni utrip.
English: Ivabradine Zentiva is available as tablets (5 and 7.5 mg) and can only be obtained with a prescription.
Slovenian: Zdravilo Ivabradine Zentiva je na voljo v obliki tablet (5 in 7,5 mg) ter se predpisuje in izdaja le na recept.
English: This is a summary of the European public assessment report (EPAR) for Ivabradine Zentiva.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Ivabradine Zentiva.
English: What measures are being taken to ensure the safe and effective use of Ivabradine Zentiva?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Ivabradine Zentiva?
English: Ivabradine Zentiva ivabradine
Slovenian: Ivabradine Zentiva ivabradin
English: The Committee recommended that Ivabradine Zentiva be approved for use in the EU.
Slovenian: Priporočil je, da se zdravilo Ivabradine Zentiva odobri za uporabo v EU.
English: Ivabradine Zentiva therefore reduces or prevents the symptoms of angina.
Slovenian: Zdravilo Ivabradine Zentiva tako zmanjša ali prepreči simptome angine pektoris.
English: The recommended starting dose is 5 mg twice a day with meals, which the doctor may increase to 7.5 mg twice a day or decrease to 2.5 mg (half a 5-mg tablet) twice a day depending on the patient's heart rate and symptoms.
Slovenian: Priporočeni začetni odmerek je 5 mg dvakrat na dan ob obrokih, ta odmerek pa lahko zdravnik odvisno od bolnikovega srčnega utripa ter simptomov pozneje poveča na 7,5 mg dvakrat na dan ali zmanjša na 2,5 mg (pol 5-miligramske tablete) dvakrat na dan.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ivabradine Zentiva have been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Ivabradine Zentiva upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Ivabradine Zentiva has been shown to have comparable quality and to be bioequivalent to Procoralan.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Ivabradine Zentiva primerljivo raven kakovosti kot zdravilo Procoralan ter da mu je biološko enakovredno.
English: Ivabradine Zentiva is a heart medicine used to treat the symptoms of long-term stable angina (pains to the chest, jaw and back, brought on by physical effort) in adults with coronary artery disease (heart disease caused by blockage of the blood vessels that supply the heart muscle).
Slovenian: Zdravilo Ivabradine Zentiva je zdravilo za bolezni srca, ki se uporablja za zdravljenje simptomov dolgotrajne stabilne angine pektoris (bolečine v prsnem košu, čeljusti in hrbtu zaradi telesnega napora) pri odraslih z boleznijo koronarnih arterij (boleznijo srca, ki jo povzroča zamašitev krvnih žil, ki dovajajo kri v srčno mišico).
English: Because Ivabradine Zentiva is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Slovenian: Ker je zdravilo Ivabradine Zentiva generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
English: For more information about treatment with Ivabradine Zentiva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Ivabradine Zentiva preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: What are the benefits and risks of Ivabradine Zentiva?
Slovenian: Kakšne so koristi in tveganja, povezani z zdravilom Ivabradine Zentiva?
English: Ivabradine Zentiva is also used in patients with long-term heart failure (when the heart cannot pump enough blood to the rest of the body) and a normal heart rhythm whose heart rate is at least 75 beats per minute.
Slovenian: Zdravilo Ivabradine Zentiva se uporablja tudi pri bolnikih z dolgotrajnim srčnim popuščanjem (kadar srce po telesu ne more črpati dovolj krvi) in normalnim srčnim ritmom, ki pa ne sme biti nižji od 75 utripov na minuto.
English: For practical information about using Ivabradine Zentiva, patients should read the package leaflet or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o uporabi zdravila Ivabradine Zentiva naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
English: This means that Ivabradine Zentiva is similar to a ‘reference medicine' already authorised in the European Union (EU) called Procoralan.
Slovenian: To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Procoralan.
English: What is Ivabradine Zentiva and what is it used for?
Slovenian: Kaj je zdravilo Ivabradine Zentiva in za kaj se uporablja?
English: It is used either in patients who cannot take beta-blockers (another type of medicine to treat angina) or in combination with a beta-blocker in patients whose disease is not controlled by a beta-blocker alone.
Slovenian: Uporablja se pri bolnikih, ki ne smejo jemati antagonistov adrenergičnih receptorjev beta (druge vrste zdravil za zdravljenje angine pektoris), ali v kombinaciji z antagonisti adrenergičnih receptorjev beta pri bolnikih, pri katerih bolezni ni mogoče nadzorovati zgolj z antagonisti adrenergičnih receptorjev beta.
English: Other information about Ivabradine Zentiva
Slovenian: Druge informacije o zdravilu Ivabradine Zentiva
English: By lowering the heart rate, Ivabradine Zentiva reduces the stress on the heart, thereby slowing the progression of heart failure and improving symptoms.
Slovenian: Zdravilo Ivabradine Zentiva z upočasnitvijo srčnega utripa zmanjša obremenitev srca ter upočasni napredovanje srčnega popuščanja in ublaži simptome.
English: Because Ivabradine Zentiva is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Procoralan.
Slovenian: Ker je zdravilo Ivabradine Zentiva generično zdravilo, so bile študije pri bolnikih omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Procoralan.
English: The active substance in Ivabradine Zentiva, ivabradine, blocks the ‘If current' in the sinus node, the natural ‘pacemaker' that regulates the heart rate.
Slovenian: Zdravilna učinkovina v zdravilu Ivabradine Zentiva, ivabradin, zavira „tok If“ v sinusnem vozlu, ki je naravni „srčni spodbujevalec“, ki uravnava srčni utrip.
English: Why is Ivabradine Zentiva approved?
Slovenian: Zakaj je bilo zdravilo Ivabradine Zentiva odobreno?
English: Ivabradine Zentiva contains the active substance ivabradine.
Slovenian: Zdravilo Ivabradine Zentiva vsebuje zdravilno učinkovino ivabradin.
English: It is not intended to provide practical advice on how to use Ivabradine Zentiva.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
English: Treatment must be stopped if the heart rate decreases persistently below 50 beats per minute or if symptoms of bradycardia (slow heart rate) continue.
Slovenian: Pri bolnikih, starejših od 75 let, se lahko uporabi manjši začetni odmerek 2,5 mg dvakrat na dan. Zdravljenje je treba prekiniti, če je srčni utrip vztrajno pod 50 utripov na minuto ali če se nadaljujejo simptomi bradikardije (počasnega srčnega utripa).
English: How has Ivabradine Zentiva been studied?
Slovenian: Kako je bilo zdravilo Ivabradine Zentiva raziskano?
English: How is Ivabradine Zentiva used?
Slovenian: Kako se zdravilo Ivabradine Zentiva uporablja?
English: How does Ivabradine Zentiva work?
Slovenian: Kako zdravilo Ivabradine Zentiva deluje?
English: QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains:
Slovenian: KAKOVOSTNA IN KOLIČINSKA SESTAVA 1 ml vsebuje:
English: 10 DATE OF REVISION OF THE TEXT <{MM/YYYY}>
Slovenian: DATUM REVIZIJE BESEDILA <{MM/LLLL}>
English: IF NECESS use.
Slovenian: ČE SO POT uporabo.
English: ATCvet code: QN05CM18.
Slovenian: Oznaka ATCvet: QN05CM18.
English: The veterinary medicinal product is intended for:
Slovenian: To zdravilo za uporabo v veterinarski medicini je namenjeno za:
English: THE WORDS "FOR ANIMAL TREATMENT ONLY" AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE
Slovenian: BESEDILO “SAMO ZA ŽIVALI” IN POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE, ČE JE SMISELNO
English: If you notice any serious effects or other effects not mentioned in this package leaflet, please inform your veterinary surgeon.
Slovenian: Če opazite kakršne koli resne neželene učinke ali druge učinke, ki niso omenjeni v teh navodilih za uporabo, obvestite veterinarja.
English: Box 374
Slovenian: P.O. Box 374
English: STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) 1 ml contains:
Slovenian: NAVEDBA ZDRAVILNE(IH) UČINKOVIN(E) IN DRUGIH SESTAVIN 1 ml vsebuje:
English: Shelf-life after first opening the container: 56 days.
Slovenian: Rok uporabnosti po prvem odpiranju vsebnika: 56 dni.
English: The administration of dexmedetomidine to puppies younger than 16 weeks and kittens younger than 12 weeks has not been studied.
Slovenian: Uporabe deksmedetomidina pri psičkih, mlajših od 16 tednov, in mačkah, mlajših od 12 tednov, niso preučevali.
English: It is recommended that animals are fasted for 12 hours prior to Sedadex administration.
Slovenian: Priporočeno je, da se živali postijo 12 ur pred uporabo zdravila Sedadex.
English: 1 ml con Dexmed (equivale
Slovenian: 1 ml vsebuj deksmedeto (ki ustreza 0
English: C/O Oriola Oy P.O.
Slovenian: C/O Oriola Oy P.O. Box 8
English: - Dogs: intravenous or intramuscular use - Cats: intramuscular use
Slovenian: - psi: intravenska ali intramuskularna uporaba - mačke: intramuskularna uporaba.
English: Pharmacotherapeutic group: Psycholeptics, hypnotics and sedatives.
Slovenian: Farmakoterapevtska skupina: Psiholeptiki, hipnotiki in sedativi.
English: MANUFACTURER'S BATCH NUMBER Lot.
Slovenian: IZDELOVALČEVA ŠTEVILKA SERIJE Serija:
English: Interactions with other medicinal products and other forms of interaction The use of other central nervous system depressants is expected to potentiate the effects of dexmedetomidine and therefore an appropriate dose adjustment should be made.
Slovenian: Medsebojno delovanje z drugimi zdravili in druge oblike interakcij Pričakuje se, da uporaba drugih zaviralcev osrednjega živčevja okrepi učinke deksmedetomidina, zato je potrebna ustrezna prilagoditev odmerka.
English: EXP {m Once bro
Slovenian: EXP {mese Načeto zdra
English: PRODULAB PHARMA B.V. Forellenweg 16, Raamsdonksveer 4941SJ
Slovenian: Forellenweg 16, Raamsdonksveer 4941SJ
English: Pharmacotherapeutic group: Psycholeptics, hypnotics and sedatives ATCvet code: QN05CM18
Slovenian: FARMAKOLOŠKE LASTNOSTI Farmakoterapevtska skupina: Psiholeptiki, hipnotiki in sedativi Oznaka ATCvet: QN05CM18.
English: Manufacturer responsible for batch release: Name:
Slovenian: Izdelovalec, odgovoren za sproščanje serij: Ime:
English: Address: Forellenweg 16 4941 SJ Raamsdonksveer The Netherlands
Slovenian: 4941 SJ Raamsdonksveer Nizozemska
English: Use during pregnancy and lactation
Slovenian: Uporaba med brejostjo in dojenjem
English: Colourless Type I glass vials of 10 ml closed with a coated bromobutyl rubber stopper and aluminium cap in a carton box.
Slovenian: 10-mililitrske viale iz brezbarvnega stekla tipa I, zaprte s prevlečenim gumijastim zamaškom iz bromobutilne gume in aluminijasto zaporko, v kartonski škatli.
English: After concurrent exposure to an overdose of dexmedetomidine (3 times the recommended dose) and 15 mg ketamine/ kg, atipamezole can be administered at the recommended dose level for reversal of effects induced by dexmedetomidine.
Slovenian: Po zaporedni izpostavitvi prevelikemu odmerku deksmedetomidina (3-kratnemu priporočenemu odmerku) in 15 mg ketamina/kg se lahko da atipamezol v priporočenem odmerku za izničenje učinkov deksmedetomidina.
English: Advice to physicians: Sedadex is an α2-adrenoreceptor agonist, symptoms after absorption may involve clinical effects including dose-dependent sedation, respiratory depression, bradycardia, hypotension, a dry mouth, and hyperglycaemia.
Slovenian: Nasvet zdravnikom: zdravilo Sedadex je agonist α2-adrenoreceptorjev, simptomi po absorpciji lahko vključujejo klinične učinke, vključno s sedacijo odvisno od odmerka, respiratorno depresijo, bradikardijo, hipotenzijo, suhimi usti in hiperglikemijo.
English: DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION
Slovenian: ODMERKI ZA POSAMEZNE ŽIVALSKE VRSTE TER POT(I) IN NAČIN UPORABE IN ZDRAVILA
English: The specific α2adrenoceptor antagonist, atipamezole, which is approved for use in animals, has been used in humans only experimentally to antagonize dexmedetomidine-induced effects.
Slovenian: Specifičen antagonist α2 adrenoreceptorjev, odobren za uporabo pri živalih, je bil pri človeku uporabljen kot antagonist učinkov deksmedetomidina samo poskusno.
English: SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED VETERINARY MEDICINAL PRODUCTS OR WASTE MATERIALS, IF ANY
Slovenian: POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEPORABLJENEGA ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI ALI ODPADNIH SNOVI, ČE OBSTAJAJO
English: The use of other central nervous system depressants is expected to potentiate the effects of dexmedetomidine and therefore an appropriate dose adjustment should be made.
Slovenian: Uporaba drugih zaviralcev osrednjega živčevja okrepi učinke deksmedetomidina, zato je treba odmerek ustrezno prilagoditi.
English: PHARMACEUTICAL FORM Solution for injection Clear, colourless solution.
Slovenian: FARMACEVTSKA OBLIKA Raztopina za injiciranje Bistra, brezbarvna raztopina
English: All anaesthetic agents used for induction or maintenance of anaesthesia should be administered to effect.
Slovenian: Vse anestetike za induciranje ali vzdrževanje anestezije je treba dajati, dokler ni dosežen učinek.
English: Sedadex contains dexmedetomidine as the active substance, which produces sedation and analgesia in dogs and cats.
Slovenian: Zdravilo Sedadex kot zdravilno učinkovino vsebuje deksmedetomidin, ki pri psih in mačkah deluje kot sedativ in analgetik.
English: 4.2 Indications for use, specifying the target species Non-invasive, mildly to moderately painful, procedures and examinations which require restraint, sedation and analgesia in dogs and cats.
Slovenian: 4.2 Indikacije za uporabo pri ciljnih živalskih vrstah Neinvazivni, blago do zmerno boleči posegi in pregledi psov in mačk, pri katerih so potrebni mirovanje, sedacija in analgezija.
English: Marketing authorisation holder: Name:
Slovenian: Imetnik dovoljenja za promet z zdravilom: Ime:
English: Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Slovenian: 6.6 Posebni varnostni ukrepi za odstranjevanje neporabljenega zdravila ali odpadnih snovi Vsako neporabljeno zdravilo za uporabo v veterinarski medicini ali odpadne snovi, ki nastanejo iz teh zdravil, je treba odstraniti v skladu z nacionalnimi zahtevami.
English: Sodium hydroxide (E 524) (for pH adjustment)
Slovenian: Natrijev hidroksid (E 524) (za uravnavo pH)
English: MARKETING AUTHORISATION NUMBER(S) EU/2/16/198/002
Slovenian: ŠTEVILKA(E) DOVOLJENJ(A) ZA PROMET EU/2/16/198/002
English: MARKETING AUTHORISATION NUMBER(S) EU/2/16/198/001
Slovenian: ŠTEVILKA(E) DOVOLJENJ(A) ZA PROMET EU/2/16/198/001
English: RINARY ME injection for
Slovenian: RMACEVTS za injiciranje
English: Hydrochloric acid (E507) (for pH adjustment)
Slovenian: Klorovodikova kislina (E 507) (za uravnavo pH)
English: W
Slovenian: V
English: BSTANCE(S
Slovenian: RAVILNE(I
English: Q 0.1 mg/m
Slovenian: KOL 0,1 mg/ml
English: Dexmedetomidine 500 micrograms/m2*
Slovenian: Deksmedetomidín 500 mikrogramov/m2*
English: The dose for cats is 40 micrograms dexmedetomidine hydrochloride/kg bw equal to a dose volume of 0.08 ml Sedadex/kg bw when used for non-invasive, mildly to moderately painful procedures requiring restraint, sedation and analgesia.
Slovenian: Odmerek za mačke je 40 mikrogramov deksmedetomidinijevega klorida/kg telesne mase, kar ustreza prostorninskemu odmerku 0,08 ml zdravila Sedadex/kg telesne mase pri uporabi za neinvazivne, blago do zmerno boleče postopke in preglede mačk, pri katerih so potrebni mirovanje, sedacija in analgezija.
English: Le Vet Beheer B.V. Wilgenweg 7
Slovenian: Le Vet Beheer B.V
English: The dose for cats is 40 micrograms dexmedetomidine hydrochloride/kg bw equal to a dose volume of 0.4 ml Sedadex/kg bw when used for non-invasive, mildly to moderately painful procedures requiring restraint, sedation and analgesia.
Slovenian: Odmerek za mačke je 40 mikrogramov deksmedetomidinijevega klorida/kg telesne mase, kar ustreza prostorninskemu odmerku 0,4 ml zdravila Sedadex/kg telesne mase pri uporabi za neinvazivne, blago do zmerno boleče postopke in preglede mačk, pri katerih so potrebni mirovanje, sedacija in analgezija.
English: CKAGING U
Slovenian: IH) UČINK
English: METHOD AN ntravenous or tramuscular u e package lea
Slovenian: ČIN IN POT nska ali intra ramuskularna bo preberite n
English: NIMAL TRE
Slovenian: NA MANJŠ
English: Dexmedetomidine hydrochloride
Slovenian: Zdravilna učinkovina: deksmedetomidinijev klorid
English: For higher weight ranges, use Sedadex 0.5 mg/ml and its dosing tables.
Slovenian: Za večje razpone telesne teže uporabite zdravilo Sedadex 0,5 mg/ml in pripadajoče odmerne preglednice.
English: ydrochloride edetomidine
Slovenian: Propilparahidroksibenzoat
English: The dose volume of atipamezole at the concentration of 5 mg/ml equals the dose volume of Sedadex 0.5 mg/ml that was given to the dog, regardless of route of administration of Sedadex.
Slovenian: Volumen odmerka atipamezola pri koncentraciji 5 mg/ml ustreza volumnu odmerka zdravila Sedadex 0,5 mg/ml, ki je bil dan psu, ne glede na način dajanja zdravila Sedadex.
English: NA
Slovenian: VEL
English: Cat Weight
Slovenian: Mačke Masa